Dipyridamole for Immune Activation in HIV
Summary
The purpose of this study is to determine if Dipyridamole (DP) will decrease inflammation in HIV-1-infected individuals who are already on antiretroviral treatment and have a low viral load.
Timeline
- Start
- 2014-07
- Primary completion
- 2017-10
- Completion
- 2017-11
Outcome
Missed primary endpoint
registry analysis (other test); ARM A: Dipyridamole for 24 Weeks vs ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks; p = 0.8220; Regression, Linear NCT02121756 ↗
registry analysis (other test); ARM A: Dipyridamole for 24 Weeks vs ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks; p = 0.0869; Regression, Linear NCT02121756 ↗
registry analysis (other test); ARM A: Dipyridamole for 24 Weeks vs ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks; p = 0.5027; Regression, Linear NCT02121756 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dipyridamole | Other / unclassified | 100 mg | — |